semaglutide cagrilintide dosage Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial cagrilintide titration schedule Comparative Efficacy

We understand that making these choices is not easy, and its important to feel supported in your journey

BioMed Central ,

Tirzepatide: FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss

Tirzepatide Tirzepatide is currently the only long-acting glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual receptor agonist

When a Reaction May Be More Concerning A tirzepatide or semaglutide injection site reaction is concerning if it is causing you significant pain, irritation or discomfort

Zepbound vs Wegovy Weight Loss Results Zepbound has demonstrated greater average weight loss in clinical trials compared to Wegovy: Zepbound led to as much as a 20.9% average reduction in body weight at the highest 15 mg dose over 72 weeks, according to results from the SURMOUNT-1 trial